About
Ascenion is an independent technology transfer company focussing on the life sciences.
It is partner to over 30 research organizations, universities and university hospitals in Germany and Europe, including life-science institutes of the Helmholtz and Leibniz Associations, the Charité, the Hannover Medical School and the Medical University of Innsbruck.
The team manages one of Europe’s biggest IP and equity portfolios from academia in the life-sciences field. Commercial opportunities include over 500 technologies and materials available for licensing, acquisition or co-development: novel therapeutic and diagnostic approaches, medical devices, digital health and AI solutions as well as platform technologies, antibodies, animal models and vectors. Ascenion’s equity portfolio of over 35 spin-off companies with several clinical-stage programs offers further attractive investment and partnering opportunities. The ingenuity and scientific excellence of Ascenion’s partners has yielded numerous successful products – including cancer drugs Ixempra and Blinatumomab – and attracted top investors and industry partners from around the globe. Ascenion has so far closed over 1,250 revenue-carrying agreements.
In 2022 Ascenion initiated the CARMA FUND which invests in early-stage projects and start-ups in the life-science and healthcare sector.
Ascenion has also initiated the pan European showcasing event BioVaria to stimulate deal making and early collaboration between Europe’s academia and the global life-sciences industry. https://www.biovaria.org/
We are looking for licensing and cooperation partners for our technologies: https://www.ascenion.de/en/technology
Disease Area / 疾患領域
Modalities / モダリティ
Business Type / 業種
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術